Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

被引：50
|
作者：
Stader, Felix [1 ,2 ,3 ]
Khoo, Saye [4 ]
Stoeckle, Marcel [1 ,2 ,3 ]
Back, David [4 ]
Hirsch, Hans H. [1 ,2 ,5 ]
Battegay, Manuel [1 ,2 ,3 ]
Marzolini, Catia [1 ,2 ,3 ,4 ]
机构：
[1] Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Dept Med, Basel, Switzerland
[2] Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Dept Clin Res, Basel, Switzerland
[3] Univ Basel, Basel, Switzerland
[4] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England
[5] Univ Basel, Dept Biomed, Transplantat & Clin Virol, Basel, Switzerland
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2020年 / 75卷 / 10期
关键词：
ENZYMES; CYP1A2; CYP3A4;
D O I：
10.1093/jac/dkaa253
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：3084 / 3086
页数：3
相关论文
共 50 条
  • [31] Evaluation of retinotoxicity of COVID-19 treatment: Hydroxychloroquine and lopinavir/ritonavir
    Burgos-Blasco, Barbara
    Guemes-Villahoz, Noemi
    Vidal-Villegas, Beatriz
    Donate-Lopez, Juan
    Garcia-Feijoo, Julian
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (02) : 644 - 646
  • [32] The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment
    Cinarka, Halit
    Gunluoglu, Gulsah
    Cortuk, Mustafa
    Yurt, Sibel
    Kiyik, Murat
    Kosar, Filiz
    Tanriverdi, Elif
    Arslan, Melih Akay
    Baydili, Kursad Nuri
    Koc, Aysu Sinem
    Altin, Sedat
    Cetinkaya, Erdogan
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2021, 51 (04) : 1624 - 1630
  • [33] Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
    Zanon, D.
    Musazzi, U. M.
    Manca, A.
    Nicolo, A. De
    D'Avolio, A.
    Cilurzo, F.
    Maximova, N.
    Tomasello, C.
    Clementi, E.
    Minghetti, P.
    DATA IN BRIEF, 2020, 33
  • [34] Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts
    Dario Cattaneo
    Mario Corbellino
    Cristina Gervasoni
    European Journal of Clinical Pharmacology, 2021, 77 : 791 - 792
  • [35] Consultation psychiatry in COVID-19 patients: Lopinavir/ritonavir interactions with main psychiatric drugs
    Marcatili, Matteo
    Stefana, Alberto
    Colmegna, Fabrizia
    di Giacomo, Ester
    D'Amico, Emiliano
    Capuzzi, Enrico
    Dakanalis, Antonios
    Clerici, Massimo
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, 75 (04) : 145 - 146
  • [36] Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19
    Binois, Yannick
    Hachad, Hafsah
    Salem, Joe-Elie
    Charpentier, Julien
    Lebrun-Vignes, Benedicte
    Pene, Frederic
    Cariou, Alain
    Chiche, Jean-Daniel
    Mira, Jean-Paul
    Nguyen, Lee S.
    KIDNEY INTERNATIONAL REPORTS, 2020, 5 (10): : 1787 - 1790
  • [37] Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts
    Cattaneo, Dario
    Corbellino, Mario
    Gervasoni, Cristina
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (05) : 791 - 792
  • [38] Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients
    Schneider, Johanna
    Jaenigen, Bernd
    Wagner, Dirk
    Rieg, Siegbert
    Hornuss, Daniel
    Biever, Paul M.
    Kern, Winfried V.
    Walz, Gerd
    PLOS ONE, 2021, 16 (05):
  • [39] Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series
    Lepage, Marc-Antoine
    Rozza, Nicholas
    Kremer, Richard
    Grunbaum, Ami
    CLINICAL TOXICOLOGY, 2021, 59 (07) : 644 - 647
  • [40] Lopinavir-ritonavir versus darunavir-norvir for hospitalized COVID-19 patients
    Paroczai, Dora
    Bikov, Andras
    Blidaru, Andreea
    Bobu, Emanuel
    Cerbu, Bianca
    Marincu, Iosif
    Mihaicuta, Stefan
    Frent, Stefan
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
12345